Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Colorectal Neoplasms 38Stomach Neoplasms 24Rectal Neoplasms 19Pancreatic Neoplasms 17Lymphoma, Large B-Cell, Diffuse 14Colonic Neoplasms 14Esophageal Neoplasms 12Adenocarcinoma Of Esophagus 12Carcinoma, Non-Small-Cell Lung 10Neoplasms 9Neoplasm Metastasis 9Adenocarcinoma 9Cholangiocarcinoma 8Biliary Tract Neoplasms 6Ovarian Neoplasms 5Parkinson Disease 4, Autosomal Dominant Lewy Body 4Esophageal Squamous Cell Carcinoma 4Carcinoma, Hepatocellular 4Lymphoma, Non-Hodgkin 3Lymphoma 3Lung Neoplasms 3Gallbladder Neoplasms 3Endometrial Neoplasms 3Carcinoma 3Bile Duct Neoplasms 3Advanced Solid Tumors 3Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Spinocerebellar Degenerations 2Recurrence 2

Interventions

Cisplatin 15pembrolizumab 14Magnetic Resonance Spectroscopy 13Specimen Handling 12Carboplatin 10Platinum 81,2-diaminocyclohexaneplatinum II citrate 8Paclitaxel 7durvalumab 6Radiotherapy, Intensity-Modulated 6Cetuximab 6cemiplimab 5Radiotherapy 5Radiation 5Pemetrexed 5Nivolumab 5Biopsy 5Ipilimumab 4Fluorouracil 41-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 4(225)Ac-DOTA-c(RGDyK) 4poly ICLC 3osimertinib 3atezolizumab 3Taxes 3Oxaliplatin 3Docetaxel 3ipatasertib 2fludarabine phosphate 2fludarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Carcinoma × Oxaliplatin × 90 days × Clear all
NCT04379596 2026-05-13

DG-03

AstraZeneca

Phase 2 Recruiting
450 enrolled
Gastrointestinal

Adenocarcinoma, Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT07281768 2026-05-06

Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Not yet recruiting
66 enrolled
Gastrointestinal

Adenocarcinoma, Carcinoma, Rectal Neoplasms, Colorectal Neoplasms

NCT06941857 2026-05-05

NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Recruiting
20 enrolled
Gastrointestinal

Carcinoma, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡